natgillin/translations-raw huggingface dataset:
Compounds of the present invention are useful in the inhibition of the production of free fatty acids. 
Spojevi prikazanog izuma su korisni u inhibiciji produkcije slobodnih masnih kiselina.
placing the outer shell (OS) in a cooled environment; 
- - vanjsko kučište (SK) se zatim stavlja u ohlađenu ambijentalnu sredinu;
is N, and Ar1 is a 6-membered aryl optionally substituted by one or more group(s) selected from halo, cyano, C1-C3 alkyl, C1-haloalkyl, and 
je H, i Ar1 je 6-člani aril izborno supstituiran s jednom ili više skupina odabranih od halo, cijano, C1-C3 alkil, C1-haloalkil, i
A recombinant gram-negative bacterial cell comprising: 
Rekombinantna gram-negativna bakterijska stanica koja sadrži: a.
omega-3-marine triglycerides; and fish oil, rich in omega-3-acids said composition formulated for transmucosal sublingual, buccal or nasal dosage. 
omega-3-morski trigliceridi; i riblje ulje, bogato u omega-3-kiselinama pri čemu je navedena kompozicija formulirana za transmukozalno sublingvalno, bukalno ili nazalno doziranje.
variable and constant light chain sequences: and 
(1) sekvenci varijabilnog i konstantnog lakog lanca:
PTA-5543; an antibody or antigen-binding fragment thereof that binds to an epitope comprising residues 82-87 of the human CD40 sequence shown in SEQ ID NO:10 or SEQ ID NO:12; 
PTA-5543; b) monoklonalnog antitijela koje se veže za epitop koji sadrži ostatke 82-87 humane CD40 sekvence prikazane u SEQ ID br.:10 ili SEQ ID br.:12;
adding cold water, stirring the resultant biphasic mixture for 20 minutes at 0°C, and isolating the crude trans-(+)-A9-tetrahydrocannabinol from the organic phase; 
razdvajanje alkoholno-kaustične faze koja sadrži trans-(-)-A9-tetrahidrokanabinol i trans-(+)-A9-tetrahidrokanabinol od prve organske faze;
The double stranded RNAi agent of claim 3, wherein the 5'-phosphate mimic is a 5'-vinyl phosphate (5'-VP). 
Dvolančani RNAi agens u skladu s patentnim zahtjevom 3, naznačen time, da je analog 5'-fosfata 5'-vinil fosfat (5'-VP).
adding a flocculating agent to remove the calcium hydroxide remaining in suspension, 
flokulatirajuće sredstvo se dodaje radi uklanjanja kalcijevog hidroksida preostalog u suspenziji, -
5% to 80% by weight of non-fibrous and non-foamed ground glass having a d90 of 5 um to 250 um, 
5% do 80 masenih % bezvlaknastog i nepjenastog smrvljenog stakla koje ima d90 određen pomoću laserske difraktometrije u rasponu od 5 do 250 µm,
A pharmaceutically acceptable liquid composition comprising 2.5% to 7% by weight levodopa; up to 2% by weight carbidopa; 5% to 18% by weight arginine; and 0.25% to 3% by weight ascorbic acid or a pharmaceutically acceptable salt thereof, wherein said composition has a pH of 9.1 to 9.8 at 25°C, and the molar ratio of levodopa plus carbidopa to the arginine is 1:1.8 to 1:3.5. 
HR P20180514 T1 PATENTNI ZAHTJEVI Farmaceutski prihvatljiv tekući sastav sadržeći 2,5% do 7% masenog udjela levodopa; do 2% masenog udjela karbidopa; 5% do 18% masenog udjela arginina; i 0,25% do 3% masenog udjela askorbinske kiseline ili farmaceutski prihvatljive soli iste, naznačeno time da spomenuti sastav ima pH vrijednost od 9,1 do 9,8 na 25", te je molarni omjer levodopa sa karbidopom u odnosu na arginin 1:1,8 do 1:3,5.
contacting a G protein-coupled receptor (GPCR) with a ligand to the GPCR in the presence of a test compound, wherein the GPCR comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 2; and 
(a) stavljanje u kontakt G protein-kupiranog receptora sa po izboru označenim poznatim ligandom za receptor u prisutnosti ili odsutnosti test spoja, pri čemu navedeni G protein kupirani receptor obuhvaća aminokiselinsku sekvencu izabranu iz skupine koju čine:
Use according to claim 15, wherein the dermatological disease is selected from atopic dermatitis, all forms of eczema, rashes of any origin or dermatoses, psoriasis and parapsoriasis groups, pityriasis rubra pilaris, bullous dermatoses, diseases of the lichenoid group, pruritis, seborrheal eczema, rosacea group, erythema exudativum multiforme, balanitis, vulvitis, manifestation of vascular diseases, hair loss, cutaneous lymphoma. 
Upotreba prema zahtjevu 15, naznačena time da je dermatološka bolest odabrana od atopijskog dermatitisa, svih oblika ekcema, osipa bilo kojeg podrijetla ili dermatoza, psorijaze i skupina parapsorijaze, Pityriasis rubra pilaris, buloznih dermatoza, bolesti iz skupine lišajeva, svraba, seboreičnog ekcema, skupine rozacea, eritema eksudativum multiforme, balanitisa, vulvitisa, mamifestacija bolesti krvnih žila, gubitka kose, kožnog limfoma.
A composition comprising the antibody including any functionally equivalent antibody or functional parts thereof according to any one of claims 1 to 7 in a therapeutically effective amount, and optionally further comprising a pharmaceutically acceptable carrier. 
Sastav koja sadrži antitijelo ili njegov funkcionalni dio prema bilo kojem od zahtjeva 1-4, naznačen time što opcijski dalje sadrži farmaceutski prihvatljiv nosač.
The treatment method according to claims 1-9 for the treatment of carbon steel parts, particularly gears and valves. 
Postupak obrade u skladu s patentnim zahtjevima 1 do 9 za obradu dijelova od čelika ugljika, naznačen time, da se naročito odnosi na zupčanike 1 ventile.
The pharmaceutical composition of claim 1, wherein the retinoid conjugate is a PEG-conjugate. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je retinoidni konjugat PEG-konjugat.
In another embodiment, the chimeric peptide comprises SEQ ID NO:69. 
Himerni peptid sukladno zahtjevu 1, naznačen time što sadrži SEQ ID NO:69.
The composition of claim 1, wherein the dispersant is at least one selected from the group consisting of a C8-12 polyoxyethylene alkyl aryl ether, a polyoxyethylene tristyrylphenyl ether, a C8-12 alkylbenzene sulfonate and a C8-18 polyoxyethylene alkyl ether phosphoric acid ester. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je sredstvo za disperziranje barem jedan odabran iz skupine koju čine C8-12 polioksietilen alkil aril eter, polioksietilen tristirilfenil eter, C8-12 alkilbenzen sulfonat i C8-18 polioksietilen alkil eter ester fosforne kiseline.
A compound as claimed in any of claims 1 to 9, for use in the treatment of psoriasis, atopic and non-atopic dermatitis, Crohn's disease, ulcerative colitis, or irritable bowel disease. 
Spoj prema zahtjevu 1, za liječenje psorijaze, atopijskog i ne-atopijskog dermatitisa, Crohnove bolesti, ulceroznog kolitisa ili iritabilne bolesti crijeva.
The chemical entity of claim 1 or 2, wherein R2 is pyrimidine substituted with one or more members independently selected from group consisting of -Cl, -F, -CH3, -CF3, -N(CH3)2, -D, or -CD3. 
Kemijski entitet prema zahtjevu 1 ili 2, gdje R? je pirimidin supstituiran sa jednim ili više članova nezavisno izabranim iz grupe koju čine -CI, -F, -CH., -CF3, -N(CH3),, -D, ili -CD:.
If the value observed exceeds the value E calculated in accordance with Colby's formula, then synergism is present. 
Ukoliko zabilježena vrijednost prelazi vrijednost E izračunanu u skladu sa Colby-jevom formulom, tada je prisutan sinergizam.
■ The reactive diluent should not introduce inappropriate physical properties to coating for the intended application. 
» - Reaktivno sredstvo za razrjeđivanje ne smije unositi neželjena fizička svojstva u prevlaku za predviđenu primjenu.
The antibody or antigen binding portion thereof according to any one of claims 1 to 8 for use according to claim 20, wherein the anti-cancer small molecule is an antimetabolite, an alkylating agent, a topoisomerase inhibitor, a microtubule-targeting agent, a kinase inhibitor, a protein synthesis inhibitor, an immunotherapeutic, a hormone or analog thereof, a somatostatin analog, a glucocortocoid, an aromatase inhibitor, an mTOR inhibitor, a small molecule targeting IGF1R or a small molecule targeting EGFR. 
(a) drugo antitijelo je anti-IGFIR antitijelo, anti-EGFR antitelo ili anti-cmet antitijelo; ili (b) sredstvo je antimetabolit, alkirajuće sredstvo, inhibitor topoizomerase, sredstvo sa ciljanim djelovanjem na mikrotubule, inhibitor kinaze, inhibitor sinteze proteina, imunoterapeutik, hormon ili njegov analog, analog somatostatina, glukokortokoid, inhibitor aromatoze, inhibitor mTOR, mala molekula koja ciljano djeluje na IGFIR ili mala molekula koja ciljano djeluje na EGFR.
The rAAV virion of claim 1, wherein the insertion site is located between amino acids corresponding to amino acids 587 and 588 of VP1 of AAV2 or the corresponding position in the capsid protein of another AAV serotype. 
Virion rAAV prema patentnom zahtjevu 7, naznačen time što je mjesto umetanja unutar aminokiselina 570-611 AAV2 kapsidnog proteina ili unutar odgovarajućeg položaja u kapsidnom proteinu drugog AAV serotipa.
In certain embodiments, an aliphatic polycarbonate provided in step (a) comprises poly(propylene carbonate). 
Postupak u skladu s patentnim zahtjevima 13 ili 14, naznačen time, da alifatski polikarbonat sadržava poli(propilen karbonat).
Correlatively, the invention relates also to a device for encoding at least one image split into partitions, such a device comprising: 
Uređaj (CO) za kodiranje barem jedne slike podijeljene u particije, te navedeni uređaj sadrži:
optionally converting a compound of Formula (I) or a tautomer or pharmaceutically acceptable salt thereof to a ester, or prodrug of Formula (I). 
ili njegov tautomer, stereoizomer, polimorf ili ester, ili farmaceutski prihvatljiva sol spoja, tautomera, stereoizomera, polimorfa ili estera.
In a preferred embodiment, an analog according to the invention may have a formula as described in the patent application WO2006110187. In a preferred embodiment, the analog may be bumetanide aldehyde, bumetanide dibenzylamide, bumetanide diethylamide, bumetanide morpholinoethyl ester, bumetanide 3-(dimethylaminopropyl) ester, bumetanide N,N-diethylglycolamide ester, bumetanide dimethylglycolamide ester, bumetanide pivaxetil ester, bumetanide methoxy(polyethyleneoxy)n-i-ethyl ester,_bumetanide benzyltrimethyl-ammonium salt, and bumetanide cetyltrimethylammonium salt. 
Spoj za uporabu u skladu bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što je spoj bumetanid ili njegov analog odabrano od: bumetanida, bumetanid aldehida, bumetanid dibenzilamida, bumetanid dietilamida, bumetanid morfolinoetil estera, bumetanid 3-(dimetilaminopropil) estera, bumetanid N,N-dietilglikolamid estera, bumetanid dimetilglikolamid estera, bumetanid pivaksetil estera, bumetanid metoksi(polietilenoksi),,-etil estera, bumetanid benziltrimetil-amonij soli i bumetanid cetiltrimetilamonij soli.
Process for the preparation of Triazole of formula (II) and salt thereof: comprising the following steps: 
Postupak priprave triazola formule (II) i njegove soli:
● taken together with the nitrogen atom to which they are bound to form an optionally substituted 5- to 8-membered heteromonocycle containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulphur. 
se uzima zajedno s atomom dušika na kojeg su vezani kako bi tvorili izborno supstituirani 5- do 8-eročlani heteromonocikl koji sadrži od jednog do tri heteroatoma, koje se bira iz skupine koju čine dušik, kisik i sumpor.
System for the sustainable cooling of industrial processes 
SUSTAV ZA ODRŽIVO HLAĐENJE INDUSTRIJSKIH POSTUPAKA
is hydrogen, or is hydrogen, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -C(=NH)NR4R5, -(CR10R11)pR12, or 
Q, je vodik, po izboru supstituirani aril, po izboru supstituirani aralkil, po izboru supstituirani cikloalkil, po izboru supstituirani cikloalkilalkil, po izboru supstituirani hetcrociklil, po izboru supstituirani hetcrociklilalkil, po izboru supstituirani heteroaril, po izboru supstituirani hetcroarilalkil, -C(=SNH)NRR:, (CRi0R11)pR12,
Method as in claim 7 and 8, characterized in that the activation of the positioning device (46) is commanded by an electrode control device (44) as a function of the arc voltage (UA) and the reference voltage (UR) received. 
Postupak prema patentnom zahtjevu 12, naznačen time što se aktiviranjem uređaja za pozicioniranje (46) upravlja preko uređaja za upravljanje elektrodom (44) kao funkcije napona luka (UA) i primljenog referentnog napona (UR).
an azaindole of formula II, wherein R5 and R6 are as defined above, is reacted under basic media with a ketone VIII, wherein R3, R4 and n are as defined above to obtain a mixture of olefins of formula IX and X, wherein R3, R4, R5, R6 and n are as defined above, hydrogenation of said olefins of formula IX and X wherein R3, R4, R5, R6 and n are as defined above followed by Boc deprotection yielded a pyrrolidino-azaindole of formula XI, wherein R3, R4, R5, R6 and n are as defined above, acylation of said pyrrolidino-azaindole of formula XI, wherein R3, R4, R5, R6 and n are as defined above is reacted with activated carboxylic acid of formula V wherein R1, R2, X and Y are as defined above to obtain the compound of formula I wherein R1, R2, R3, R4, R5, R6, X and Y are as defined above, 
azaindol sa formulom II, pri čemu R5 i R6 su kako je gore definirano, reagira u bazičnom mediju sa ketonom VIII, pri čemu R3, R4 i n su kako je gore definirano da se dobije smjesa olefina sa formulom IX i X, pri čemu R3, R4, R5, R6 i n su kako je gore definirano, hidrogenacijom navedenih olefina sa formulom IX i X pri čemu R3, R4, R5, R6 i n su kako je gore definirano, te zatim Boc deprotekcijom dolazi se do pirolidino-azaindola sa formulom XI, pri čemu R3, R4, R5, R6 i n su kako je gore definirano, acilacijom navedenog pirolidino-azaindola sa formulom XI, pri čemu R3, R4, R5, R6 i n su kako je gore definirano dolazi do reakcije sa aktiviranom karboksilnom kiselinom sa formulom V pri čemu R1, R2, X i Y su kako je gore definirano da se dobije spoj sa formulom I pri čemu R1, R2, R3, R4, R5, R6, X i Y su kako je gore definirano,
In these studies, it was found that 5-HT1A receptor antagonists would abolish the initial brake on 5-HT neurotransmission induced by the serotonin reuptake inhibitors and thus produce an immediate boost of 5-HT transmission and a rapid onset of therapeutic action. 
U tim se studijama otkrilo da bi antagonisti receptora 5-HT,a mogli poništiti početnu kočnicu neurotransmisije 5-HT uzrokovanu inhibitorima ponovne pohrane serotonina te tako trenutno stimulirali transmisiju 5-HT i izazvati brzi terapeutski učinak.
A pyrogen-free composition comprising the compound or pharmaceutically acceptable salt thereof of any of the preceding claims and an acceptable carrier, for use in treating a patient suffering from or susceptible to diabetic neuropathic pain. 
Apirogeni sastav obuhvaća tvar ili njenu farmaceutski prihvatljivu sol iz bilo kojeg od prethodnih patentnih zahtjeva i prihvatljivi nosač.
The precipitate was recrystallised from methanol to give the title compound (6.5 g) as a white solid, m.p. 
Talog so rekristalizira iz metanola tako da se dobiva naslovni spoj (6,5 g) u obliku bijele čvrste supstance, t.t.
BACKGROUND The present invention generally relates to capsules for containing beverage ingredients, to a beverage producing system comprising such capsules as well as to methods for producing beverages on the basis of ingredients contained in such capsules. 
Predmetni izum se općenito odnosi na čahure koje sadržavaju sastojke za napitke, na sustav za proizvodnju napitka koji sadržavaju takve čahure, kao i na postupak za proizvodnju napitaka na osnovi sastojaka koji su sadržani u takvim čahurama.
Use according to claim 9 wherein the formulation comprises benzyl alcohol, phenol and/or m-cresol. 
Uporaba sukladno zahtjevu 4, pri čemu formulacija sadrži benzil alkohol, fenol i/ili m-kresol.
water is added to the melphalan flufenamide hydrochloride (J1) solution in order to obtain an aqueous melphalan flufenamide hydrochloride (J1) solution, in a concentration of 0.2-3.0 mg/ml; 
dodaje se voda otopini melfalan flufenamid hidroklorida (J1) da bi se dobila vodena otopina melfalan flufenamid hidroklorida (J1), u koncentraciji od 0,2 - 3,0 mg/ml;
Furthermore, the monohydrochloride salt shows better profile of stability to oxidation conditions than other salts. as shown in the experimental data included in Example 4. 
Nadalje, monohidrokloridna sol ima bolji profil stabilnosti na oksidacijske uvjete u odnosu na druge soli kao što je pokazano u eksperimentalnim podacima uključenim u Primjer 4.
Process according to one of the claims 1 to 6, wherein the at least one water-soluble acid of step b) has a pKa from 0 to 6, preferably has a pKa from 0 to 2.5. 
Postupak prema jednom od zahtjeva 1 do 5, naznačen time da barem jedna kiselina koja se otapa u vodi iz koraka b) ima pK, od 0 do 6, poželjno ima pK, od 0 do 2.5.
Methacrylic Acid Copolymer 
Kopolimer metakrilne kiseline
The sole for shoes according to claim 4, wherein said rings made of plastic material are overmolded on edges of said net elements. 
Potplat za cipele u skladu s patentnim zahtjevom 4, naznačen time, da se navedeni prstenovi, izrađeni od plastičnog materijala (123), prešaju i oblikuju preko rubova navedenih mrežastih elemenata (120).
A probe consistent with this embodiment is or is complementary to a sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2. 
(li) se spomenuta DNA proba sastoji od SEQ ID NO: 1 ili SEQ ID NO: 2 ili njihovih komplementarnih sekvenci; i /ili
A compound of Formula (I), or a therapeutically acceptable salt thereof, for use in treating cancer in a mammal in recognized need of such treatment, wherein R1, R2, and R3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, cyano, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, NRARB and (NRARB)carbonyl; 
Spoj Formule (I) [image] ili njegova terapijski prihvatljiva sol, naznačena time, da, R2 i R3 su neovisno odabrani iz skupine koja se sastoji od vodika, alkenila, alkoksi, alkoksikarbonil alkila, alkinila, cijano, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, nitro, NRARB i (NRARB)karbonila;
A process for the production of expanded plastic materials, comprising a hot moulding phase of a starting polymeric blend comprising a polymeric matrix, isocyanate, anhydride and catalyst inside a mould, characterized in that the heating of said blend is effected by making the same a heat source, by triggering in its interior an exothermic reaction represented by the following trimerization reaction from isocyanate to isocyanurate: said reaction being triggered by supplying heat from the outside of said mould. 
HR P20150246 T1 PATENTNI ZAHTJEVI Postupak proizvodnje ekspandiranih plastičnih materijala, obuhvaća fazu vrućeg lijevanja u kalup početne polimerne smjese koja sadrži polimerni matriks, izocijanat, anhidrid 1 katalizator, naznačen time što zagrijavanje te smjese počinje tako da ona sama bude izvor topline, tako da se potakne u njezinoj unutrašnjosti egzotermna reakcija predstavljena sljedećom reakcijom trimerizacije izocijanata u izocijanurat:
a non-unitary formulation) comprising the lactate salt and the one or more other therapeutic agent together with instructions for the extemporaneous association of the at least one compound to form a physical association of the two or more compounds/agents; or 
nejedinstveni pripravak) koji sadrži laktatnu sol i jedno ili više drugih terapeutskih sredstava zajedno s uputama za ekstremno povezivanje najmanje jednog spoja kako bi se formiralo fizičko povezivanje dvaju ili više spojeva / sredstava; ili e
An immunogenic composition comprising a pharmaceutically acceptable carrier and a composition according to any one of claims 1 to 13. 
Imunogeni sastav, naznačen time, da sadrži farmaceutski prihvaljiv nogač i sastav prema bilo kojem od zahtjeva 1 do 13.
or a pharmaceutically acceptable salt, solvate, or solvate of salt thereof. A compound selected from: 
je Hal, LA, O(LA), Cyc1 ili Cyc2, ili njegova farmaceutski prihvatljiva sol, solvat ili solvat soli.
The method of claim 7, wherein the coating consists essentially of a co-processed microfibrillated cellulose and inorganic particulate material composition. 
prvu poroznost manju od druge poroznosti papirnog proizvoda koji ne sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala; i/ili
is hydrogen, halo, or C1-3alkyl substituted with one, two, or three halo, or with - ORh; 
je vodik, halo ili C1-3alkil supstituiran s jednim, dva ili tri halo ili sa - ORh;
The deuterium-substituted or isotopically labeled compound according to claim 1 or a pharmacologically acceptable salt thereof, or a solvate or hydrate thereof, wherein the compound represented by the formula (1) is 
13. Spoj u skladu sa patentnim zahtjevom 1 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje spoj predstavljen formulom (1) je
The method of claim 31, wherein a population of rAAV particles with empty capsids, partially denatured capsids, and/or partially full capsids are bound to the HIC medium after the elution with the medium salt buffer. 
Postupak prema bilo kojem od zahtjeva 1 do 8, naznačen time što je populacija čestica rAAV s praznim kapsidima, djelomično denaturiranim kapsidima, manje zaraznim kapsidnim materijalom, i/ili djelomično punim kapsidima vezana na HIC medij nakon eluiranja s puferom srednje koncentracije soli.
The aqueous layer was made acidic (pH˜1-2) using 6.0 N hydrochloric acid, and the resulting solid was extracted with ethyl acetate (2×75 mL). 
Vodeni sloj je zakiseljen (pH - 1-2) primjenom 6.0 N klorovodične kiseline, i dobivena čvrsta supstanca je ekstrahirana sa etil acetatom (2 x 75 mL).
infecting the grown MDCK-derived cells with an influenza virus; 
(Cc) zaraza uzgojenih MDCK-deriviranih stanica virusom gripe;
The active agent, buprenorphine, may be included in the device in a drug reservoir, drug matrix or drug/adhesive layer. 
Djelatni sastojak, buprenorfin, može se uključiti u uređaj u spremnik za lijek, matriks lijeka ili ljepljivi sloj s lijekom.
The pharmaceutical composition for use according to Claim 2, wherein the treatment further comprises administering to the patient a second therapeutic agent, optionally selected from a thrombolytic agent, a chemotherapeutic agent, a neuroprotective agent, an anti-inflammatory agent, a steroid, a cytokine, or a growth factor. 
Rekombinantna molekula protutijela ili njezin fragment koji veže a4, za uporabu prema zahtjevu 3, naznačena time, da liječenje dodatno obuhvaća primjenu na pacijentu nekog drugog terapeutskog sredstva koje je opcijski odabrano od sljedećih: trombolitičko sredstvo, kemoterapeutsko sredstvo, neuroprotektivno sredstvo, protuupalno sredstvo, steroid, citokin ili faktor rasta.
The method of claim 12, wherein the tumor cell is selected from the group consisting of a colorectal cancer cell, NSCLC (non-small cell lung cancer) cell, gastric cancer cell, pancreatic cancer cell and breast cancer cell. 
Protutijelo ili pripravak za uporabu prema zahtjevu 18, naznačen/o time, da je rak odabran iz skupine koja se sastoji od raka debelog crijeva, raka ne-malih stanica pluća (NSCLC), raka želuca, raka gušterače i raka dojke.
The tube of claim 3, characterized in that the working pair formed by the adsorbate and the adsorbent (1.2.4) is methanol-active carbon or ammonia-active carbon. 
Cijev iz zahtjeva 3, naznačena time da je radni par oblikovan od adsorbata i adsorbenta (1.2.4) metanol - aktivan ugljik ili amonij - aktivan ugljik.
at least one gateway (6; 18), provided for transferring messages from the telecommunication network (2) onto power lines of the power distribution network (4) and vice versa, the messages on the power lines being in a predetermined frequency band used for power line communication, 
- < najmanje jedan usmjernik protokola (gateway, 6; 18) za prijenos poruka od telekomunikacijske mreže (2) na elektroenergetsku mrežu (4) i obrnuto, pri čemu se poruke u elektroenergetskoj mreži nalaze u pojasu unaprijed određene frekvencije koji se koristi za komunikaciju preko elektroenergetske mreže,